Literature DB >> 16961066

Interleukin-18 and transforming growth factor-beta 1 plasma levels in Alzheimer's disease and vascular dementia.

Lucia Malaguarnera1, Massimo Motta, Michelino Di Rosa, Massimiliano Anzaldi, Mariano Malaguarnera.   

Abstract

Inflammation has been involved in the development of dementia in cerebrovascular diseases. To investigate the cellular activation of the peripheral immune system in patients with Alzheimer's disease (AD) and vascular dementia (VaD), we determined the presence of IL-18 and TGF-beta1 in the plasma by using ELISA. The levels of IL-18 and TGF-beta1 were significantly elevated in patients with AD and VaD compared to non-demented, age-matched subjects. We found an inverse correlation between the levels of IL-18 and TGF-beta1 in AD patients. In VaD patients, the correlation between IL-18 and TGF-beta1 reached a borderline positive value. Whereas, in the non-demented, age-matched subjects, a positive correlation between IL-18 and TGF-beta1 levels was observed. These findings indicate that IL-18 and TGF-beta1 elevation is associated with AD and VaD patients, confirming that the immune system might exert a remarkable role in the development and progression of neurodegenerative disorders. Moreover, as different modifications were detected in the patients affected by AD and VaD, we propose that IL-18 and TGF-beta1 plasma levels might represent possible differential biomarkers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16961066     DOI: 10.1111/j.1440-1789.2006.00701.x

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  31 in total

1.  Simvastatin restored vascular reactivity, endothelial function and reduced string vessel pathology in a mouse model of cerebrovascular disease.

Authors:  Xin-Kang Tong; Edith Hamel
Journal:  J Cereb Blood Flow Metab       Date:  2015-01-07       Impact factor: 6.200

Review 2.  The role of inflammasome in Alzheimer's disease.

Authors:  Li Liu; Christina Chan
Journal:  Ageing Res Rev       Date:  2014-02-19       Impact factor: 10.895

3.  Interleukin-18 -137 G/C and -607 C/A polymorphisms and Alzheimer's disease risk: a meta-analysis.

Authors:  Jiaojiao Zhang; Tingting Song; Hua Liang; Jie Lian; Guanjun Zhang; Huilin Gong
Journal:  Neurol Sci       Date:  2016-02-20       Impact factor: 3.307

Review 4.  The Distinct Role of ADAM17 in APP Proteolysis and Microglial Activation Related to Alzheimer's Disease.

Authors:  Meng Qian; Xiaoqiang Shen; Huanhuan Wang
Journal:  Cell Mol Neurobiol       Date:  2015-06-29       Impact factor: 5.046

5.  Interleukin 18 gene polymorphisms predict risk and outcome of Alzheimer's disease.

Authors:  Paola Bossù; Antonio Ciaramella; Maria Luisa Moro; Lorenza Bellincampi; Sergio Bernardini; Giorgio Federici; Alberto Trequattrini; Fabio Macciardi; Ilaria Spoletini; Fulvia Di Iulio; Carlo Caltagirone; Gianfranco Spalletta
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-02-13       Impact factor: 10.154

Review 6.  Interleukin 18 in the CNS.

Authors:  Silvia Alboni; Davide Cervia; Shuei Sugama; Bruno Conti
Journal:  J Neuroinflammation       Date:  2010-01-29       Impact factor: 8.322

Review 7.  NLRP3 inflammasomes are involved in the progression of postoperative cognitive dysfunction: from mechanism to treatment.

Authors:  Shuai Zhao; Fan Chen; Dunwei Wang; Wei Han; Yuan Zhang; Qiliang Yin
Journal:  Neurosurg Rev       Date:  2020-09-12       Impact factor: 3.042

Review 8.  Peripheral chemo-cytokine profiles in Alzheimer's and Parkinson's diseases.

Authors:  M Reale; N H Greig; M A Kamal
Journal:  Mini Rev Med Chem       Date:  2009-09       Impact factor: 3.862

9.  Hydrogen sulfide attenuates neuronal injury induced by vascular dementia via inhibiting apoptosis in rats.

Authors:  Li-Mei Zhang; Cai-Xiao Jiang; Dian-Wu Liu
Journal:  Neurochem Res       Date:  2009-06-02       Impact factor: 3.996

Review 10.  Signaling pathways regulating neuron-glia interaction and their implications in Alzheimer's disease.

Authors:  Hong Lian; Hui Zheng
Journal:  J Neurochem       Date:  2015-11-30       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.